NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 10.26 against a street estimate of 10.77 — a miss of 4.7%.
with an average price target of ₹1,661.20.
MIXED DBF grew 14% with insulin and semaglutide strong; margins compressed 300bps due to biologics mix shift. Swiss Parenterals softens outlook; FY27 guidance maintained at 14% (300bps ahead of 11% market). Bhopal facility commercializes August. Q1 FY27 Consolidated revenue +13% YoY; DBF +14%; exports flattish-to-low single-digit. Analysts focused on underperforming OAD (+2%) and cardiac (+11% vs market +15%), Swiss Parenterals slowdown, and semaglutide adoption headwinds. Management attributed therapy misses to prior product bans and field lapses (now refocused), Swiss to facility remediation, and semaglutide to patient hesitation—not supply or price—with turnaround confidence anchored on past execution. 2026-07-29…
Full summary in the app.
| Document | Date |
|---|---|
| Annual report FY2026 ERIS LIFESCIENCES LIMITED - ANNUAL REPORT FY2025-26 SUMMARY HEADLINE NUMBERS • Operating Revenue: Rs. 3,129 crore (8% YoY growth) • EBITDA: Rs. 1,12 | 2026-09-02 |
| Q1 FY27 earnings call | 2026-08-04 |
| Investor presentation ERIS LIFESCIENCES LIMITED – Q1 FY27 INVESTOR PRESENTATION SUMMARY HEADLINE NUMBERS • Domestic Branded Formulations (DBF) Revenue: ₹801 cr, up 14.2% | 2026-07-29 |
| Investor presentation · Q4 FY26 ERIS LIFESCIENCES LIMITED - CORPORATE PRESENTATION SUMMARY HEADLINE NUMBERS • Revenue FY26: INR 3,129 cr (vs INR 2,894 cr FY25; growth 8%) • EBITDA | 2026-06-23 |
| Q4 FY26 earnings call ERIS LIFESCIENCES LIMITED - DOCUMENT SUMMARY HEADLINE NUMBERS • Document is a regulatory notification dated 26 May 2026 regarding Q4 FY26 (quarter an | 2026-05-26 |
| Quarterly results · Q4 FY26 ERIS LIFESCIENCES LIMITED – COMPANY DOCUMENT SUMMARY --- HEADLINE NUMBERS • FY 2026 Net Profit After Tax (Consolidated): Rs 647.51 Crore (attributa | 2026-05-20 |
| Investor presentation | 2026-05-20 |
| Investor presentation · Q3 FY26 ERIS LIFESCIENCES LIMITED – CORPORATE PRESENTATION SUMMARY February 2026 --- HEADLINE NUMBERS • Revenue FY25: INR 2,894 crore; 9MFY26: INR 2,373 cr | 2026-02-20 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹7.21 / share ex-date May 29, 2026 | 2026-05-29 |
| Announcement | Date |
|---|---|
| Closure of acquisition of Probiotics business from Velbiom Eris Lifesciences Limited has completed the acquisition of the Probiotics business from Velbiom Probiotics Private Limited. This is a strategic move to expand Eris's product portfolio into t | 2026-03-31 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Eris Lifesciences Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.